title: FDG PET or PET/CT in patients with pancreatic cancer: when does it add to diagnostic CT or MRI?
abstract: OBJECTIVE
  Assess the impact of FDG-PET or PET/CT (PI) on pancreatic cancer management when added to CT or MRI (CDI).
  
  
  METHODS
  Forty-nine patients underwent 79 PI exams. Discordant findings on PI and CDI were assessed for clinical impact.
  
  
  RESULTS
  Fifteen of 79 PI-CDI pairs were discordant. Ten of 79 PI favorably and 5 of 79 unfavorably altered management. PI favorably altered management more often when ordered for therapy monitoring compared to staging [risk ratio 13.00 (95% CI 1.77-95.30)] or restaging [risk ratio 18.5 (95% CI 2.50-137.22)].
  
  
  CONCLUSIONS
  PI favorably alters management more often when used for therapy monitoring compared to staging or restaging.
authors: Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. ojavery@partners.org
authors: Omar
authors: O
authors: Javery
authors: Paul
authors: P
authors: Shyn
authors: Koenraad
authors: K
authors: Mortele
mesh_terms: D000368:Aged; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D064847:Multimodal Imaging; D009367:Neoplasm Staging; D010190:Pancreatic Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology; D049268:Positron-Emission Tomography; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D014057:Tomography, X-Ray Computed